Jun 25, 2020 / 03:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by. And welcome to the Bristol-Myers Squibb Hematology Investor Call. (Operator Instructions) I would now like to introduce your host for today's conference call, Mr. Tim Power. You may begin.
Timothy Power - Bristol-Myers Squibb Company - VP & Head of IR
Thanks, Kevin. And good morning, everyone. Thanks for joining us again today for the second of our three-part investor series. Today, we are focusing on hematology. And again, today, we'll have a presentation followed by a Q&A session. So if you're not participating by the webcast, you should be able to go ahead and download the materials on bms.com.
Joining me this morning for the presentation are Giovanni Caforio, our Chairman and Chief Executive Officer; Samit Hirawat, Chief Medical Officer, Global Drug Development; and Nadim Ahmed, President of Hematology. But also with me for the Q&A session are Chris Boerner, Chief Commercialization Officer; Rupert Vessey, Executive Vice President, Research and Early Development; David Elkins, Chief
Bristol-Myers Squibb Co Three-Part Investor Series: Hematology Transcript
Jun 25, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers